Jeff Yass’s TScan Therapeutics TCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-23,623
Closed -$23.2K – 14526
2026
Q2
$23.2K Sell
23,623
-133,605
-85% -$142K ﹤0.01% 13013
2026
Q1
$159K Sell
157,228
-58,905
-27% -$62.9K ﹤0.01% 11940
2025
Q4
$216K Buy
216,133
+136,373
+171% +$197K ﹤0.01% 10714
2025
Q3
$145K Sell
79,760
-64,612
-45% -$114K ﹤0.01% 11306
2025
Q2
$209K Buy
144,372
+95,769
+197% +$138K ﹤0.01% 11118
2025
Q1
$67.1K Buy
48,603
+22,768
+88% +$49.2K ﹤0.01% 11758
2024
Q4
$78.5K Buy
25,835
+15,659
+154% +$71K ﹤0.01% 11476
2024
Q3
$50.7K Buy
+10,176
New +$61.4K ﹤0.01% 11371
2024
Q2
– Sell
-297,902
Closed -$2.37M – 13219
2024
Q1
$2.37M Buy
297,902
+193,954
+187% +$1.22M ﹤0.01% 4969
2023
Q4
$606K Buy
103,948
+87,033
+515% +$398K ﹤0.01% 8189
2023
Q3
$43.3K Buy
+16,915
New +$39.5K ﹤0.01% 11360

Other funds holding TCRX

Jeff Yass's TCRX Position: Q3 2026 in Review

Jeff Yass sold out of TScan Therapeutics (TCRX) in Q3 2026, closing a stake of 23,623 shares — an estimated $23.2K sold.

Jeff Yass first reported a position in TCRX in Q3 2023 and held it in 11 quarters. The position peaked at $2.37M in Q1 2024. 52 funds tracked by Wall St. Rank hold TCRX as of Q3 2026.

  • Jeff Yass reported no remaining TScan Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Jeff Yass sold 23,623 TScan Therapeutics shares in Q3 2026, an estimated $23.2K.
  • Jeff Yass first reported a position in TScan Therapeutics in Q3 2023 and held it in 11 quarters.
  • Jeff Yass's TScan Therapeutics position peaked at $2.37M in Q1 2024.
  • 52 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.